This is a summary of the European public assessment report (EPAR) for Vipdomet. It explains how the European Medicines Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Vipdomet. For practical information about using Vipdomet, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Vipdomet is indicated in the treatment of adult patients aged 18 years and older with type-2 diabetes mellitus: - as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin; - in combination with pioglitazone (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone; - in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.
Therapeutic Area (MeSH)
N/AATC Code
A10BD13
ATC Item
metformin and alogliptin
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
N/AINN / Common Names
N/AEMA Name
Vipdomet
Medicine Name
Vipdomet
Aliases
N/ANo risk management plan link.
